Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImClone C225 Compassionate Use On Hold Pending New Manufacturing Plant

Executive Summary

ImClone Systems will consider restarting a compassionate use program for the epidermal growth factor receptor IMC-C225 when production begins at a newly constructed manufacturing plant, CEO Samuel Waksal, MD, told the House Government Reform Committee June 20.

You may also be interested in...



ImClone Erbitux Hearing Will Include Five FDAers Under Subpoena

The House Energy & Commerce/Oversight Subcommittee has subpoenaed five FDA witnesses to appear at a June 13 hearing on issues surrounding the refuse-to-file letter for ImClone's Erbitux

ImClone Erbitux Hearing Will Include Five FDAers Under Subpoena

The House Energy & Commerce/Oversight Subcommittee has subpoenaed five FDA witnesses to appear at a June 13 hearing on issues surrounding the refuse-to-file letter for ImClone's Erbitux

Bristol Paying $2 Bil. For ImClone C225; New Milestone For Inlicensing Deals?

Bristol-Myers Squibb's $2 bil. investment in ImClone's anti-cancer monoclonal antibody C225 (cetuximab) represents a $500 mil. premium to the company's estimate of the peak annual sales potential for the agent.

Related Content

UsernamePublicRestriction

Register

PS038074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel